Recurrent Respiratory Papillomatosis

Respiratory
2
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Precigen
PrecigenGERMANTOWN, MD
2 programs
1
1
Zopapogene imadenovecPhase 41 trial
PRGN-2012 - Phase I; Dose Level 1Phase 1/21 trial
Active Trials
NCT04724980Active Not Recruiting38Est. Jun 2026
NCT06538480Recruiting30Est. Dec 2028
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
MicrodebriderN/A1 trial
Active Trials
NCT03465280Unknown400Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
PrecigenZopapogene imadenovec
PrecigenPRGN-2012 - Phase I; Dose Level 1
Alder TherapeuticsMicrodebrider

Clinical Trials (3)

Total enrollment: 468 patients across 3 trials

NCT06538480PrecigenZopapogene imadenovec

Zopa Retreatment and Vector Shedding in Adults With RRP

Start: Jul 2024Est. completion: Dec 202830 patients
Phase 4Recruiting
NCT04724980PrecigenPRGN-2012 - Phase I; Dose Level 1

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Start: Mar 2021Est. completion: Jun 202638 patients
Phase 1/2Active Not Recruiting

Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)

Start: Apr 2018Est. completion: Aug 2022400 patients
N/AUnknown

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 468 patients
2 companies competing in this space